Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 9Neoplasms 5Prostatic Neoplasms 3Solid Tumors 2Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Cancers 1Skin Diseases 1Prostatic Neoplasms, Castration-Resistant 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

enzalutamide 14Docetaxel 7radium Ra 223 dichloride 6Abiraterone Acetate 6Prednisone 5darolutamide 4abiraterone 3olaparib 2niraparib 2atezolizumab 2apalutamide 2zimberelimab 1xentuzumab 1tasquinimod 1sacituzumab govitecan 1sabizabulin 1quemliclustat 1ipatasertib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1Rosuvastatin Calcium 1Radium-223 1Pluvicto 1Pioglitazone 1Nivolumab 1JNJ-64619178 1JNJ-64264681 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms, Castration-Resistant × ipatasertib × Clear all
NCT04404140 2023-10-17

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Hoffmann-La Roche

Phase 1 Terminated
6 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡